Appili Therapeutics Inc Class A (TSE:APLI) has released an update.
Appili Therapeutics Inc. has amended its arrangement agreement with Aditxt, Inc. and increased the deadline for the acquisition of its Class A common shares to August 30, 2024. Additionally, the company has raised its bridge loan amount from C$300,000 to C$400,000 with Bloom Burton & Co. Inc. These financial moves aim to support Appili’s mission in drug development for infectious diseases and medical countermeasures.
For further insights into TSE:APLI stock, check out TipRanks’ Stock Analysis page.
